Clinical Study Report
A 24-week, randomised, double-blind, placebo-controlled study of xanomeline transdermal therapeutic system in patients with mild to moderate Alzheimer’s disease
Report information
- Protocol
- NVT-AD-3001
- Compound
- Xanomeline transdermal therapeutic system
- Study phase
- Phase 2
- Indication
- Mild to moderate Alzheimer’s disease
- Sponsor
- Nordvale Therapeutics
- Report version
- 1.0
- Report date
- 2026-07-28
- Status
- Draft
This document is a draft and is not for regulatory submission.
Available renderings
The report and its companion Statistical Analysis Plan are rendered from one project, each in both formats below.
| Output | Format |
|---|---|
| Book | HTML site, one page per section. |
| Book | Typst PDF, chapters in one file. |
| Single document | HTML, the whole report on one page. |
| Single document | Typst PDF, rendered from csr.qmd. |
| Statistical Analysis Plan | HTML, the companion SAP rendered from sap.qmd. |
| Statistical Analysis Plan | Typst PDF, the companion SAP rendered from sap.qmd. |
This document contains confidential information belonging to Nordvale Therapeutics. Except as may be otherwise agreed in writing, by accepting or reviewing this document you agree to hold this information in confidence and not to disclose it to others, nor to use it for unauthorised purposes.
Nordvale Therapeutics is a fictional sponsor. This Clinical Study Report is a Quarto demonstration built from the public CDISC pilot data shipped with pharmaverseadam, and is not a regulatory submission. It was built by Mickaël Canouil (source).